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Abstract
Background: To report a case of masquerade syndrome presenting as bilateral uveitis in an HCV
positive patient, and to highlight the difficulties in distinguishing between chronic uveitis and
malignancy-induced inflammation.
Case report: In January 2005 a 54-year-old Caucasian man was referred to the Ophthalmological
Department for bilateral visual loss, severe vitritis, and a significant cataract in both eyes. His clinical
history was significant for HCV infection. The uveitis treated with low dose of steroids and
immunosuppressors, yielding a partial remission of the symptoms. One year later he developed a
Primary Central Nervous System Lymphoma. In January 2007 he returned to our department for
cataract surgery. The patient underwent phacoemulsification of the cataract in the right eye,
intraocular lens implantation and intravitreal injections of 4 mg triamcinolone acetonide. After one
month fundus biomicroscopy showed a solid lesion at the posterior pole, consistent with a retinal
relapse of the Primary Central Nervous System Lymphoma. Restaging investigations were
unremarkable and ruled out a disease relapse, and a diagnostic vitrectomy showed only rare
inflammatory cells. In view of the progressive swelling of the retinal lesions we decided to treat the
patient with intravitreal Methotrexate. Complete remission of the retinal lesions with retinal
scarring was achieved after 12 months. In May 2008 the patient underwent phacoemulsification of
the cataract in the left eye and intraocular lens implantation. A vitreal tap was performed and was
positive for rare abnormal cells CD45+, CD20-. Vitreous sampling did not yield enough cells for a
diagnosis of monoclonality. No systemic or intravitreal therapy was performed because of the
absence of central nervous system relapses, the small number of atypical cells found in the vitreous
sample and the absence of retinal masses. After three months the patient developed a central
nervous system relapse of the lymphoma and rapidly died.
Conclusion: In elderly patients suffering from uveitis a masquerade syndrome should always be
suspected. Vitreous sampling may not yield enough cells for diagnosis and the vitritis may be
steroid-sensitive, at least initially. This makes a differential diagnosis between chronic uveitis and
malignancy-induced inflammation very difficult.
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Background
The incidence of true immune-mediated uveitis declines
in the elderly. Infection endophthalmitis, especially aris-
ing after surgery, and malignancy occur at higher fre-
quency. In this age group, the suspicion of a masquerade
syndrome, particularly a primary CNS non-Hodgkin's
lymphoma, should always be raised [1]. We describe a
case of an immunocompetent HCV+ patient referred to
the Ophthalmological Department of Bari University
Hospital for bilateral uveitis. The inflammation, initially
diagnosed as a complication of the chronic hepatitis C
virus, was, instead, the first manifestation of a primary
central nervous system lymphoma, that was diagnosed
one year later.
Case presentation
In January 2005 a 54-year-old Caucasian immunocompe-
tent man was referred to the Ophthalmological Depart-
ment for bilateral visual loss (right eye: 20/100 and left
eye: 20/60), severe vitritis, cells in the anterior chamber
and a significant cataract in both eyes. In both eyes the
intraocular pressure (IOP) was 15 mmHg.
His clinical history was significant for HCV infection
treated with interferon, and for insulin dependent diabe-
tes. The bilateral ocular uveitis was correlated to the HCV
infection and treated with low dose of steroids and immu-
nosuppressors, yielding a partial remission of the symp-
toms. One year later the patient developed neurological
symptoms, (a slow-down in mental and motility perform-
ance and a central defect of the VII cranial nerve) that led
to a cranial CT examination and to the diagnosis of Pri-
mary Central Nervous System Lymphoma (PCNSL) aris-
ing from the left nuclei of the base, the nucleus caudatus,
the anterior arm of the internal capsule, the insula and
thalamus(stereotaxically diagnosed as CD45+, CD20+,
CD3neg, CD10neg, Td Tneg, ki-67/MIB-1 = 90%), treated
with L-VAMP multi chemotherapy and radiotherapy,
resulting incomplete recovery.
In January 2007 he returned to our department for a dete-
rioration of the visual acuity(only light perception in the
right eye and 20/200 in the left eye). He presented a total
white cataract in the right eye and a severe cataract affect-
ing the visus in the left eye. There were rare inflammatory
cells in the anterior chamber of both eyes. Ultrasono-
graphic examination showed a severe vitritis and a small,
solid uplift at the posterior pole, misinterpreted as macula
cystoids edema in the right eye and a mild vitritis in the
left eye.
The patient underwent phacoemulsification of the cata-
ract in the right eye, acrylic hydrophilic intraocular lens
implantation and intravitreal injections of 4 mg triamci-
nolone acetonide. After one month, best corrected visual
acuity in the right eye was 20/40, IOP was 17 mmHg, fun-
dus biomicroscopy showed a solid, irregular whitish
lesion at the posterior pole temporally to the macula, con-
sistent with a retinal relapse of the PCNSL (Figure 1).
Restaging investigations (CT, MRI, spinal tap, osteomed-
ullary biopsy) were unremarkable and ruled out a disease
relapse, and a vitreal tap and subsequent diagnostic vitrec-
tomy showed only rare inflammatory cells.
In view of the progressive swelling of the retinal lesions
(Figure 2), the absence of indications for systemic therapy
and the risk of visual loss secondary to radiotherapy, we
decided to treat the patient with local chemotherapy in
the form of intravitreal Methotrexate(IMTX), as suggested
by other authors [2,3].
After obtaining written informed consent, surgery was
performed, together with full asepsis, preoperative clean-
ing of the conjunctival sac with povidone-iodine 5%, top-
ical anesthesia with topical benoxinate HCL 0.4% drops.
Then 400 μg/0.1 ml of IMTX were intravitreally injected
via the pars plana using a 30 gauge needle. Eight twice
weekly intravitreal methotrexate injections were adminis-
tered during the induction phase, followed by eight
weekly consolidation injections. Subsequently, a mainte-
nance phase involved nine monthly methotrexate injec-
tions to complete one year of treatment (25 injections). At
each visit, measurement of the visual acuity (VA) and
intraocular pressure (IOP) was made, as well as slit lamp
biomicroscopy to view individual cells within the vitreous
cavity, and dilated fundoscopy to see malignant cellular
infiltrates involving the retina. Gonioscopic examination
was added to the monitoring protocol to identify iris and
anterior chamber angle neovascularisation. The retinal
Baseline Figure 1
Baseline. Fundus biomicroscopy one month after cataract 
surgery and intravitral injection of triamcinolone acetonide 
revealed solid, irregular whitish lesions at the posterior pole, 
consistent with a retinal relapse of the PCNSL.Cases Journal 2009, 2:152 http://www.casesjournal.com/content/2/1/152
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lesions showed a progressive, rapid regression as from the
first administration of the intravitreal therapy (Figure 3,
Figure 4 and Figure 5). After 12 months the retinal lesions
had been replaced by retinal scarring (Figure 6), best cor-
rected visual acuity in the right eye increased to 20/20. We
did not observe any ophthalmic or systemic side effects
related to IMTX, such as corneal epitheliopathy, maculop-
athy, vitreous hemorrhage, optic atrophy or sterile endo-
phthalmitis. Restaging investigations (TC, RMN, spinal
tap, osteomedullary biopsy) were performed periodically
and ruled out a disease relapse.
In May 2008 the patient underwent phacoemulsification
of the cataract in the left eye and acrylic hydrophilic
intraocular lens implantation. A vitreal tap was performed
and was positive for rare abnormal cells CD45+, CD20-.
Vitreous sampling did not yield enough cells for a diagno-
sis of monoclonality, the hallmark of malignant proc-
esses.
After one month, visual acuity in left eye was 20/20, there
was a mild vitritis and no retinal lesions. A new restaging
of the disease was performed and no relapse was detected.
No systemic or intravitreal therapy was performed
because of the absence of central nervous system relapses,
Fundus biomicroscopy 45 days after cataract surgery showed  a progressive swelling of the retinal lesions Figure 2
Fundus biomicroscopy 45 days after cataract surgery 
showed a progressive swelling of the retinal lesions.
Fundus biomicroscopy 15 days after the first IMTX revealed  a partial regression of the retinal lymphomatous infiltrates Figure 3
Fundus biomicroscopy 15 days after the first IMTX 
revealed a partial regression of the retinal lymphom-
atous infiltrates.
Fundus biomicroscopy after 8 IMTX Figure 4
Fundus biomicroscopy after 8 IMTX.
Fundus biomicroscopy after 12 IMTX revealed a further  regression of the malignancy Figure 5
Fundus biomicroscopy after 12 IMTX revealed a fur-
ther regression of the malignancy.Cases Journal 2009, 2:152 http://www.casesjournal.com/content/2/1/152
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the small number of atypical cells found in the vitreous
sample and the absence of retinal masses.
Unfortunately, after three months the patient developed a
central nervous system relapse of the lymphoma and rap-
idly died of the malignancy and the toxic effect of the new
high dosage systemic chemotherapy.
Discussion
Primary central nervous system lymphoma
(PCNSL)accounts for 4 to 7% of brain tumours. It occurs
with a markedly increased incidence in the immunosup-
pressed population but its incidence has increased in the
past two decades in immunocompetent patients as well
[4-6], probably due to the better diagnostic imaging and
biopsy sampling methods available in recent years.
Primary intraocular lymphoma (PIOL), is a subset of pri-
mary central nervous system lymphoma (PCNSL), in
which lymphoma cells invade the subretinal pigment epi-
thelial space and vitreous cavity, with or without central
nervous system involvement at the time of the ocular
diagnosis. The age of onset of PIOL ranges from 15 to 85
years, with a mean age of the late 50s to early 60s. Both
sexes are affected but most series point to a higher inci-
dence in women.
Typical clinical symptoms of PIOL include blurred vision
and floaters. In many of these patients uveitis is initially
diagnosed, especially if there is no known history of cere-
bral involvement. The most common ophthalmic mani-
festations are similar to those seen in patients with
posterior uveitis or vitreitis, combined anterior and poste-
rior uveitis, or subretinal pigment epithelial infiltrates [7].
Without treatment, PIOL is often rapidly fatal, especially
when associated with PCNSL. Currently, the five year sur-
vival rate ranges from less than 20% to 34% with the best
therapy [8,9]. It is imperative, then, to make a prompt
diagnosis so that life extending treatment may be started.
The diagnosis of intraocular lymphoma can be very diffi-
cult patients with intraocular lymphoma may seem per-
fectly well with no systemic or neurological symptoms
and signs, peripheral blood, bone marrow cytology and
cellular morphology are usually normal and therefore
unhelpful. Ocular examination can be helpful, but the
degree of vitritis is highly variable and retinal lesions may
or may not be found. Even in the presence of retinal
lesions, doing a biopsy is hazardous, may miss the lesion,
and if successful, will only yield a small number of cells.
A vitreous sample can also be unhelpful, as in our patient,
because it will only yield a small number of atypical cells
so it is not possible to determine the monoclonality, or it
may yield only inflammatory cells. This makes the differ-
entiation between chronic inflammation and intraocular
lymphoma very difficult [10].
In our case, the diagnosis was delayed because initially the
ocular inflammation was correlated to the hepatitis C. The
patient presented only few ocular signs and seemed per-
fectly well, with no systemic or neurological symptoms
and signs. Moreover, the ocular vitritis showed a partial
response to the mild steroid and immunosuppressive
therapy instituted.
Only one year later the patient developed neurological
symptoms, (a slow-down in mental and motility perform-
ance and a central defect of the VII cranial nerve) that led
to a cranial CT examination and to the diagnosis of central
nervous system lymphoma.
When the correct diagnosis of the ocular pathology was
made, after extracting the cataractin the right eye few ther-
apeutic options were available, because the patent had
just undergone systemic chemo and radiotherapy, and
refused eye enucleation.
Intrathecal therapy was not recommended because of the
complete absence of relapse of the CNS disease. Eye radi-
otherapy could cause eye dryness, actinic retinopathy,
optic neuropathy and resulting irreversible severe visual
loss.
The response to IMTX was fast and an improvement of the
visual acuity and a regression of the retinal lesions were
observed within 8 weeks. We did not observe any ophthal-
mic side effects such as corneal epitheliopathy, maculop-
Fundus biomicroscopy: Complete remission of the retinalle- sions was achieved after 12 months of IMTX therapy, when  the retinal masses had beencompletely replaced by retinal  scars (25 IMTX) Figure 6
Fundus biomicroscopy: Complete remission of the 
retinallesions was achieved after 12 months of IMTX 
therapy, when the retinal masses had beencom-
pletely replaced by retinal scars (25 IMTX).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cases Journal 2009, 2:152 http://www.casesjournal.com/content/2/1/152
Page 5 of 5
(page number not for citation purposes)
athy, vitreous hemorrhage, optic atrophy or sterile
endophthalmitis.
Despite the good results of the systemic chemotherapy,
radiotherapy and intravitreal therapy in the right eye, and
the negative results of all the precedent restaging examina-
tions, after three months the patient developed a new,
fatal PCNSL localization. This case confirms the very poor
prognosis of these malignancies, especially in cases of
relapse.
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